Clinical trial
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PREVAIL)
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PREVAIL)
An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 128 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Open Label Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines
Actual Study Start Date: December 2016
Actual Primary Completion Date: April 2018
Actual Study Completion Date: March 2019
Arms:
- Experimental: ALD403 (Eptinezumab) Dose Level 1
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 128 |
| Actual Study start date | 01 December 2016 |
| Actual study completion date | 01 March 2019 |